CA2947283C - Substituted oxo-1,6-dihydro-pyrimidinyl compounds as inhibitors of lysine specific demethylase-1 - Google Patents

Substituted oxo-1,6-dihydro-pyrimidinyl compounds as inhibitors of lysine specific demethylase-1 Download PDF

Info

Publication number
CA2947283C
CA2947283C CA2947283A CA2947283A CA2947283C CA 2947283 C CA2947283 C CA 2947283C CA 2947283 A CA2947283 A CA 2947283A CA 2947283 A CA2947283 A CA 2947283A CA 2947283 C CA2947283 C CA 2947283C
Authority
CA
Canada
Prior art keywords
fluoro
oxo
dihydro
methy1
pyrimidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2947283A
Other languages
English (en)
French (fr)
Other versions
CA2947283A1 (en
Inventor
Young K. Chen
Toufike Kanouni
Stephen W. Kaldor
Jefrey Alan Stafford
James Marvin Veal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Quanticel Research Inc
Original Assignee
Celgene Quanticel Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Quanticel Research Inc filed Critical Celgene Quanticel Research Inc
Publication of CA2947283A1 publication Critical patent/CA2947283A1/en
Application granted granted Critical
Publication of CA2947283C publication Critical patent/CA2947283C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Polyamides (AREA)
CA2947283A 2014-05-01 2015-04-30 Substituted oxo-1,6-dihydro-pyrimidinyl compounds as inhibitors of lysine specific demethylase-1 Active CA2947283C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461987354P 2014-05-01 2014-05-01
US61/987,354 2014-05-01
PCT/US2015/028635 WO2015168466A1 (en) 2014-05-01 2015-04-30 Inhibitors of lysine specific demethylase-1

Publications (2)

Publication Number Publication Date
CA2947283A1 CA2947283A1 (en) 2015-11-05
CA2947283C true CA2947283C (en) 2023-01-24

Family

ID=54354743

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2947283A Active CA2947283C (en) 2014-05-01 2015-04-30 Substituted oxo-1,6-dihydro-pyrimidinyl compounds as inhibitors of lysine specific demethylase-1

Country Status (32)

Country Link
US (9) US9255097B2 (show.php)
EP (1) EP3137169B1 (show.php)
JP (1) JP6493890B2 (show.php)
KR (1) KR102400920B1 (show.php)
CN (1) CN106659914B (show.php)
AR (1) AR100251A1 (show.php)
AU (1) AU2015253040B2 (show.php)
BR (1) BR112016025248B1 (show.php)
CA (1) CA2947283C (show.php)
CL (1) CL2016002736A1 (show.php)
CY (1) CY1124959T1 (show.php)
DK (1) DK3137169T3 (show.php)
EA (1) EA036672B8 (show.php)
ES (1) ES2903423T3 (show.php)
HR (1) HRP20220096T1 (show.php)
HU (1) HUE057895T2 (show.php)
IL (1) IL248505B (show.php)
LT (1) LT3137169T (show.php)
MX (1) MX373373B (show.php)
NI (1) NI201600165A (show.php)
PE (1) PE20161438A1 (show.php)
PH (1) PH12016502179A1 (show.php)
PL (1) PL3137169T3 (show.php)
PT (1) PT3137169T (show.php)
RS (1) RS62874B1 (show.php)
SA (2) SA519410025B1 (show.php)
SG (1) SG11201609033TA (show.php)
SI (1) SI3137169T1 (show.php)
SM (1) SMT202200066T1 (show.php)
TW (1) TWI676620B (show.php)
WO (1) WO2015168466A1 (show.php)
ZA (1) ZA201607613B (show.php)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105899491B (zh) 2014-01-17 2019-04-02 诺华股份有限公司 用于抑制shp2活性的1-哒嗪-/三嗪-3-基-哌(-嗪)/啶/吡咯烷衍生物及其组合物
WO2015107494A1 (en) 2014-01-17 2015-07-23 Novartis Ag 1 -(triazin-3-yi_/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
RS62874B1 (sr) 2014-05-01 2022-02-28 Celgene Quanticel Research Inc Inhibitori lizin specifične demetilaze-1
CN106660987B (zh) * 2014-06-27 2020-11-06 赛尔基因昆蒂赛尔研究公司 赖氨酸特异性脱甲基酶-1的抑制剂
SMT202200136T1 (it) * 2014-07-03 2022-05-12 Celgene Quanticel Research Inc Inibitori della demetilasi lisina-specifica-1
US20180284095A1 (en) 2015-06-12 2018-10-04 Oryzon Genomics, S.A. Biomarkers associated with lsd1 inhibitors and uses thereof
CN107922388B (zh) 2015-06-19 2020-12-29 诺华股份有限公司 用于抑制shp2活性的化合物和组合物
ES2741746T3 (es) 2015-06-19 2020-02-12 Novartis Ag Compuestos y composiciones para inhibir la actividad de SHP2
EP3310771B1 (en) 2015-06-19 2020-07-22 Novartis AG Compounds and compositions for inhibiting the activity of shp2
WO2017013061A1 (en) 2015-07-17 2017-01-26 Oryzon Genomics, S.A. Biomarkers associated with lsd1 inhibitors and uses thereof
PL3371152T3 (pl) * 2015-11-05 2021-06-28 Celgene Quanticel Research, Inc. Kompozycje zawierające inhibitor specyficznej dla lizyny demetylazy-1 mający pierścień pirymidynowy i jego zastosowanie w leczeniu nowotworów
WO2017079476A1 (en) 2015-11-05 2017-05-11 Mirati Therapeutics, Inc. Lsd1 inhibitors
DK3381896T3 (da) * 2015-11-27 2023-03-27 Taiho Pharmaceutical Co Ltd Biphenylforbindelse eller salt deraf
JP6916795B2 (ja) 2015-12-29 2021-08-11 ミラティ セラピューティクス， インコーポレイテッド Ｌｓｄ１阻害剤
WO2017157825A1 (en) 2016-03-15 2017-09-21 F. Hoffmann-La Roche Ag Combinations of lsd1 inhibitors for use in the treatment of solid tumors
WO2017158136A1 (en) 2016-03-16 2017-09-21 Oryzon Genomics, S.A. Methods to determine kdm1a target engagement and chemoprobes useful therefor
US10150754B2 (en) 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
PT3468972T (pt) 2016-06-14 2020-08-21 Novartis Ag Compostos e composições para inibir a atividade da shp2
MX381059B (es) 2016-08-10 2025-04-01 Celgene Quanticel Res Inc Tratamiento de tumores y linfomas no de hodgkin sólidos, reincididos y/o refractarios.
JP2019532953A (ja) * 2016-09-30 2019-11-14 ノバルティス アーゲー 増強された有効性を有する免疫エフェクター細胞治療
US20190256930A1 (en) 2016-11-03 2019-08-22 Oryzon Genomics, S.A. Biomarkers for determining responsiveness to lsd1 inhibitors
WO2018083138A1 (en) 2016-11-03 2018-05-11 Oryzon Genomics, S.A. Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agents
CA3048340A1 (en) 2017-01-10 2018-07-19 Novartis Ag Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor
ES2991090T3 (es) 2017-03-30 2024-12-02 Univ Freiburg Albert Ludwigs Inhibidores de KDM4
KR102361918B1 (ko) 2017-05-26 2022-02-14 다이호야쿠힌고교 가부시키가이샤 신규 비페닐 화합물 또는 그의 염
WO2018216795A1 (ja) * 2017-05-26 2018-11-29 大鵬薬品工業株式会社 新規なビフェニル化合物を用いた抗腫瘍効果増強剤
AU2018276611B2 (en) 2017-05-31 2022-01-06 Taiho Pharmaceutical Co., Ltd. Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1
RS66336B1 (sr) 2017-08-03 2025-01-31 Oryzon Genomics Sa Postupci za lečenje bihejvioralnih poremećaja
RU2020133727A (ru) * 2018-03-21 2022-04-21 Сучжоу Пухе Биофарма Ко., Лтд. Ингибиторы shp2 и их применение
CN109668987A (zh) * 2019-02-27 2019-04-23 浙江华贝药业有限责任公司 一种3-氨基哌啶二盐酸盐对映异构体测定分析方法
CN120837494A (zh) 2019-03-20 2025-10-28 奥莱松基因组股份有限公司 使用kdm1a抑制剂如化合物伐菲德司他治疗注意缺陷多动症的方法
CN113613653A (zh) 2019-03-20 2021-11-05 奥莱松基因组股份有限公司 治疗边缘型人格障碍的方法
EP3983016A4 (en) 2019-06-13 2023-06-07 Celgene Corporation CANCER TREATMENT METHODS BY TARGETING COLD TUMORS
MX2021015992A (es) * 2019-06-20 2022-04-06 Celgene Quanticel Res Inc Azacitidina en combinación con venetoclax, gilteritinib, midostaurina u otros compuestos para tratamiento de leucemia o síndrome mielodisplásico.
EP3994280A1 (en) 2019-07-05 2022-05-11 Oryzon Genomics, S.A. Biomarkers and methods for personalized treatment of small cell lung cancer using kdm1a inhibitors
US20220411381A1 (en) * 2019-10-01 2022-12-29 Bayer Aktiengesellschaft Pyrimidinedione derivatives
PL4058151T3 (pl) 2019-11-13 2025-08-04 Taiho Pharmaceutical Co., Ltd. Nowa sól związku terfenylowego
US20230089536A1 (en) * 2020-03-06 2023-03-23 Celgene Quanticel Research, Inc. Combination of an lsd-1 inhibitor and nivolumab for use in treating sclc or sqnsclc
WO2021247977A1 (en) 2020-06-05 2021-12-09 Celgene Quanticel Research, Inc. Methods of treating prostate cancer
CN117015540A (zh) * 2021-03-11 2023-11-07 南京明德新药研发有限公司 噻吩类化合物及其应用
CN117062813A (zh) * 2021-03-24 2023-11-14 四川汇宇制药股份有限公司 一种多环化合物及其应用
WO2022214303A1 (en) 2021-04-08 2022-10-13 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors for treating myeloid cancers
JP2025516647A (ja) 2022-05-09 2025-05-30 オリゾン・ゲノミクス・ソシエダッド・アノニマ Ｌｓｄ１阻害薬を用いる悪性末梢神経鞘腫（ｍｐｎｓｔ）の治療法
US20250295660A1 (en) 2022-05-09 2025-09-25 Oryzon Genomics, S.A. Methods of treating nf1-mutant tumors using lsd1 inhibitors
WO2024110649A1 (en) 2022-11-24 2024-05-30 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors and menin inhibitors for treating cancer
EP4626878A1 (en) 2022-12-02 2025-10-08 Neumora Therapeutics, Inc. Methods of treating neurological disorders

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5550147A (en) * 1992-02-05 1996-08-27 Fujisawa Pharmaceutical Co., Ltd. Pyrazole derivatives, processes for preparation thereof and pharmaceutical composition comprising the same
EP1087963B1 (en) 1998-06-19 2004-08-25 Chiron Corporation Inhibitors of glycogen synthase kinase 3
EP1397142A4 (en) * 2001-06-19 2004-11-03 Bristol Myers Squibb Co PYRIMIDINE PHOSPHODIESTERASE (PDE) INHIBITORS 7
KR101052482B1 (ko) * 2002-11-21 2011-07-28 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 포스포티딜이노시톨(ｐｉ) 3-키나제 억제제인 2,4,6-삼치환피리미딘 및 암의 치료에서 이들의 사용
US7183287B2 (en) * 2003-04-03 2007-02-27 Pharmacia Corporation Substituted pyrimidinones
TW200526641A (en) * 2003-12-26 2005-08-16 Daiichi Seiyaku Co Amidopyrazole derivatives
US8466163B2 (en) 2006-12-11 2013-06-18 Bionomics Limited Furo[2,3-d]pyrimidines and related compounds and methods for treating disease states by inhibiting tubulin polymerization
ES2597903T3 (es) * 2008-07-29 2017-01-24 Boehringer Ingelheim International Gmbh 5-Alquinil-pirimidinas
TWI435874B (zh) * 2008-10-31 2014-05-01 Toray Industries 環己烷衍生物及其醫藥用途
WO2011143057A1 (en) * 2010-05-11 2011-11-17 Merck Sharp & Dohme Corp. Novel prolylcarboxypeptidase inhibitors
WO2012034116A2 (en) 2010-09-10 2012-03-15 The Johns Hopkins University Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders
JP5813855B2 (ja) 2011-03-25 2015-11-17 グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｎｏ．２ Ｌｉｍｉｔｅｄ Ｌｓｄ１阻害剤としてのシクロプロピルアミン
JP6195828B2 (ja) 2012-05-24 2017-09-13 出光興産株式会社 有機エレクトロルミネッセンス素子用材料、及びそれを用いた有機エレクトロルミネッセンス素子
US8980879B2 (en) 2013-03-11 2015-03-17 Abbvie Inc. Bromodomain inhibitors
WO2015018522A1 (en) 2013-08-06 2015-02-12 Oncoethix Sa Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl)
CA3148196A1 (en) 2013-10-18 2015-04-23 Celgene Quanticel Research, Inc. Bromodomain inhibitors
LT3080100T (lt) * 2013-12-11 2023-02-27 Celgene Quanticel Research, Inc. Lizinui specifinės demetilazės-1 inhibitoriai
RS62874B1 (sr) * 2014-05-01 2022-02-28 Celgene Quanticel Research Inc Inhibitori lizin specifične demetilaze-1
US20160022684A1 (en) 2014-07-25 2016-01-28 Pharmacyclics Llc Bet inhibitor and bruton's tyrosine kinase inhibitor combinations
US20190055235A1 (en) 2014-12-17 2019-02-21 Zenith Epigenetics Ltd. Substituted bicyclic compounds as bromodomain inhibitors
PL3371152T3 (pl) * 2015-11-05 2021-06-28 Celgene Quanticel Research, Inc. Kompozycje zawierające inhibitor specyficznej dla lizyny demetylazy-1 mający pierścień pirymidynowy i jego zastosowanie w leczeniu nowotworów

Also Published As

Publication number Publication date
MX2016014253A (es) 2017-02-08
IL248505B (en) 2021-01-31
CN106659914A (zh) 2017-05-10
US20200231549A1 (en) 2020-07-23
SMT202200066T1 (it) 2022-03-21
US10207999B2 (en) 2019-02-19
US20220153706A1 (en) 2022-05-19
ES2903423T3 (es) 2022-04-01
US9573930B2 (en) 2017-02-21
EA201692079A1 (ru) 2017-04-28
JP6493890B2 (ja) 2019-04-03
US20170114024A1 (en) 2017-04-27
HRP20220096T1 (hr) 2022-04-15
US20160130247A1 (en) 2016-05-12
AU2015253040B2 (en) 2020-04-09
AU2015253040A8 (en) 2017-06-15
BR112016025248B1 (pt) 2022-12-13
CY1124959T1 (el) 2023-01-05
HUE057895T2 (hu) 2022-06-28
US20150315187A1 (en) 2015-11-05
TWI676620B (zh) 2019-11-11
EA036672B8 (ru) 2021-01-13
SA516380201B1 (ar) 2019-11-20
US20170349555A1 (en) 2017-12-07
KR102400920B1 (ko) 2022-05-20
EP3137169A1 (en) 2017-03-08
US11084793B2 (en) 2021-08-10
WO2015168466A8 (en) 2016-11-24
US20160152595A1 (en) 2016-06-02
US10023543B2 (en) 2018-07-17
EP3137169B1 (en) 2021-11-10
AR100251A1 (es) 2016-09-21
SA519410025B1 (ar) 2022-06-01
EP3137169A4 (en) 2018-01-10
IL248505A0 (en) 2016-12-29
CN106659914B (zh) 2020-06-19
NI201600165A (es) 2017-03-13
US10654810B2 (en) 2020-05-19
US9771329B2 (en) 2017-09-26
US20180325900A1 (en) 2018-11-15
US9255097B2 (en) 2016-02-09
SI3137169T1 (sl) 2022-04-29
US9776974B2 (en) 2017-10-03
BR112016025248A2 (pt) 2018-06-19
PL3137169T3 (pl) 2022-02-28
CA2947283A1 (en) 2015-11-05
CL2016002736A1 (es) 2017-06-23
SG11201609033TA (en) 2016-11-29
JP2017514830A (ja) 2017-06-08
PH12016502179A1 (en) 2017-02-13
RS62874B1 (sr) 2022-02-28
PE20161438A1 (es) 2017-01-18
TW201623254A (zh) 2016-07-01
US20170349556A1 (en) 2017-12-07
KR20160144506A (ko) 2016-12-16
EA036672B1 (ru) 2020-12-07
DK3137169T3 (da) 2022-02-14
ZA201607613B (en) 2017-11-29
MX373373B (es) 2020-05-12
AU2015253040A1 (en) 2016-11-24
US11987560B2 (en) 2024-05-21
LT3137169T (lt) 2022-04-11
PT3137169T (pt) 2022-01-25
WO2015168466A1 (en) 2015-11-05
NZ725914A (en) 2023-09-29

Similar Documents

Publication Publication Date Title
CA2947283C (en) Substituted oxo-1,6-dihydro-pyrimidinyl compounds as inhibitors of lysine specific demethylase-1
US11028066B2 (en) Inhibitors of lysine specific demethylase-1
JP6663866B2 (ja) リジン特異的なデメチラーゼ−１の阻害剤
NZ725914B2 (en) Inhibitors of lysine specific demethylase-1
HK1235332A1 (en) Inhibitors of lysine specific demethylase-1
HK1235332B (en) Inhibitors of lysine specific demethylase-1
HK1231860B (en) Inhibitors of lysine specific demethylase-1
HK1231860A1 (en) Inhibitors of lysine specific demethylase-1

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200403

EEER Examination request

Effective date: 20200403

EEER Examination request

Effective date: 20200403

EEER Examination request

Effective date: 20200403

EEER Examination request

Effective date: 20200403

EEER Examination request

Effective date: 20200403

EEER Examination request

Effective date: 20200403